跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT07130604
NCT07130604招募中3 期

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis

InventisBio Co., Ltd1 个研究点 分布在 1 个国家目标入组 390 人开始时间: 2025年9月18日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
招募中
入组人数
390
试验地点
1
主要终点
The percentage of subjects with at least 90% improvement in PASI
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is a randomized, double-blind, placebo-controlled multicenter clinical trial targeting subjects with moderate to severe plaque psoriasis.

详细描述

This study is a randomized, double-blind, placebo-controlled multicenter clinical trial targeting subjects with moderate to severe plaque psoriasis, with a total of 390 subjects planned to be enrolled.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 70 Years（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Subject voluntarily takes part in the study after being fully informed,signs a written ICF, and agrees to follow procedures specified in the study protocol;
  • •Plaque psoriasis assessed by the investigator as suitable for systemic treatment and stable (defined as stable as no significant outbreak of morphological change or disease activity assessed by the investigator) for at least 6 months prior to signing informed consent;
  • •During the screening period and before taking the investigational drug for the first time, psoriatic surface area (BSA) ≥10%, PGA score ≥ 3, PASI score ≥ 12;
  • •Hematology, Blood chemistry and Urinalysis examination were basically normal.

排除标准

  • •Erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, reverse psoriasis, drug-induced psoriasis;
  • •Have other skin lesions that affect the evaluation of treatment outcomes, such as eczema;
  • •History of herpes zoster/herpes simplex, or presence of herpes zoster/herpes simplex infection during the screening period;
  • •Have a history of tuberculosis, or active tuberculosis, or latent tuberculosis, or suspected clinical manifestations of tuberculosis infection;
  • •Other conditions that the investigator considers inappropriate for participation in the study.

研究组 & 干预措施

D-2570 group1

Experimental

干预措施: D-2570 (Drug)

D-2570 group2

Experimental

干预措施: D-2570 (Drug)

Placebo group

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

The percentage of subjects with at least 90% improvement in PASI

时间窗: Day 1-Day 112

The percentage of subjects with at least 90% improvement in PASI from baseline at week 16 of treatment.

次要结局

  • Percentage of subjects with a PGA(Day1-Day365)
  • The percentage of subjects with at least 75% improvement in PASI(Day1-Day365)
  • The percentage of subjects with at least 90% improvement in PASI(Day1-Day365)
  • The percentage of subjects with at least 100% improvement in PASI(Day1-Day365)
  • The percentage of subjects with improvement in PASI(Day1-Day365)
  • Percentage of subjects with a PGA score of 0 or 1 and ≥2 points from baseline(Day1-Day365)
  • Percentage of subjects with baseline ss-PGA score ≥3(Day 1-Day 112)
  • Percentage of subjects with baseline PGA-F score ≥3(Day 1-Day 112)
  • Percentage of subjects with baseline pp-PGA score ≥3(Day 1-Day 112)
  • Percentage of subjects with baseline DLQI score ≥2(Day 1-Day 112)
  • The main PK parameters -Time to maximum measured plasma concentration -Tmax Population pharmacokinetic characteristics of D-2570(Day1-Day365)
  • The main PK parameters#Area under the plasma concentration versus time curve-AUC(Day1-Day365)
  • The main PK parameters-Vz/F (apparent volume of distribution)(Day1-Day365)
  • The main PK parameters Half-life -t1/2(Day1-Day365)
  • The main PK parameters-CL/F (apparent clearance)(Day1-Day365)
  • Weight and height will be combined to report BMI in kg/m^2(Day1-Day365)
  • Incidence and severity of AEs based on NCI CTCAE V5.0(Day1-Day365)
  • Incidence and severity of TEAEs based on NCI CTCAE V5.0(Day1-Day365)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
2 期
Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque PsoriasisPlaque Psoriasis
NCT06278350InventisBio Co., Ltd161
招募中
1 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by VirusesSevere Viral Pneumonia(Not Include COVID-19)
NCT06693362Ruijin Hospital60
Unknown
4 期
Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS).Ankylosing Spondylitis
NCT04934059China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.60
已完成
Phase 3 4
Study of the efficacy and safety of DHATREE in polycystic ovary syndrome.
CTRI/2023/02/049915Gangwal Healthcare Pvt Ltd68
已完成
2 期
Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea TypeIrritable Bowel Syndrome of Diarrhea Type (IBS-D)
NCT05923892Otsuka Beijing Research Institute87
Evaluate the Efficacy and Safety of D-2570 in... | 临床试验